TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2012293
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin
Study: 25920709
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), followed by six adjuvant 28‐day cycles of either dose‐dense (150 mg/m(2), days 1‐7, 15‐21) or metronomic (50 mg/m(2), days 1‐28) temozolomide, and maintenance RA (100 mg/m(2), days 1‐21/28) until disease progression.
Study: 22030896
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg two times a day)
Study: 6428290
Drug: L-thyroxine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine therapy
Study: 31084985
Drug: RIPCmultiple (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIPCmultiple (daily RIPC for 6 days plus RIPC during 40 min before LPS), n=10
Study: 21907422
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg once daily on top of conventional treatment
Study: 21719107
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus insulin glulisine (glargine/glulisine)
Study: 21719107
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin analogues
Study: 18160344
Drug: Intervention (nurse-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (nurse-led lifestyle counselling and preparation for surgery at monthly intervals)
Study: 16822451
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and a thieno-pyridine
Study: 14679093
Drug: Insulin (Ins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (Ins group)
Study: 8688986
Drug: Erdosteine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (300 mg x 2/day) with amoxycillin (1500 mg/day)
Study: 8688986
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with amoxycillin (1500 mg/day)
Study: 2244610
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium (40 to 50 mg/kg per day for 10 days)
Study: 2244610
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (30 to 40 mg/kg per day for 10 days)
Study: 2244610
Drug: Cephalexin monohydrate
Normalized name: Cephalexin Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin monohydrate (40 to 50 mg/kg per day for 10 days)
Study: 19128368
Drug: Rimonabant followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimonabant followed by Metformin
Study: 25161160
Drug: Metformin only
Normalized name: Metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin only
Study: 7976695
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) - 30 mg weekly for one month, then monthly for one year
Study: 7976695
Drug: Interferon Alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon Alpha 2B (IFN) - 50 million units weekly for 3 months, then monthly for one year
Study: 17274828
Drug: CQR-300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQR-300 (300 mg daily)
Study: 29912570
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn starch, 300 mg daily)
Study: 28284844
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (target dose: 15-20mg/week)
Study: 25967706
Drug: Boswellia-based cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia-based cream (Bosexil(R))
Study: 17685703
Drug: CHO+P gel
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+P gel (0.15 g CHO + 0.038 g protein x kg BW(-1))
Study: 17685703
Drug: CHO gel
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO gel (0.15 g CHO x kg BW(-1))
Study: 17685703
Drug: CHO+P gel
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+P gel
Study: 17685703
Drug: CHO gel
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO gel
Study: 3339726
Drug: Doxorubicin twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin twice weekly for 6 weeks
Study: 3339726
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after transurethral resection
Study: 30091218
Drug: SAR425899 (0.01-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR425899 (0.01-0.1 mg single ascending doses)
Study: 30091218
Drug: SAR425899 (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR425899 (daily doses over 21 or 28 days)
Study: 27736032
Drug: High-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose unfractionated heparin (100 units kg-1 bolus)
Study: 27736032
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (50 units kg-1 bolus)
Study: 23839107
Drug: CYD tetravalent
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD tetravalent dengue vaccine (TDV)
Study: 21172891
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of induction course 1 with various induction schedules
Study: 21172891
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine
Study: 21172891
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with GO
Study: 12487322
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata extract SHA-10 fixed combination, Kan Jang, taken for 5 days
Study: 9796558
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg b.d. for 5 days)
Study: 9796558
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg b.d. for 7 days)
Study: 8585285
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine using immunopotentiating reconstituted influenza virosomes (IRIV)
Study: 8585285
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine using IRIV with all five vaccines
Study: 8585285
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine with halved quantity of Di‐Te antigen
Study: 8585285
Drug: Di‐Te vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di‐Te vaccination in the combination
Study: 8585285
Drug: Alum‐adsorbed single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum‐adsorbed single vaccines
Study: 2495813
Drug: Alinidine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 30 mg alone
Study: 2495813
Drug: Alinidine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 30 mg + Atenolol 25 mg
Study: 2495813
Drug: Alinidine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 30 mg + Nifedipine retard 20 mg
Study: 2495813
Drug: Alinidine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 30 mg + Glyceryl trinitrate 500 micrograms
Study: 29703990
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia with propofol sedation
Study: 29703990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (propofol sedation without topical pharyngeal anesthesia)
Study: 22353786
Drug: Mometasone cream
Normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone cream (0.1%)
Study: 22353786
Drug: Mometasone comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone comparator (fatty cream with mometasone furoate 0.1%)
Study: 16012273
Drug: SSRI antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressants
Study: 11239615
Drug: MPA/E(2)C (Lunelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA/E(2)C (Lunelle Monthly Contraceptive Injection)
Study: 11239615
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral contraceptives
Study: 8986246
Drug: E.P.D. (Enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: E.P.D. (Enzyme Potentiated Desensitization) immunotherapy, administered via intradermal injection at extremely low doses once a year for seasonal allergies and twice a year for non-seasonal allergies
Study: 1592650
Drug: Adjuvant portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant portal infusion (5‐Fluorouracil, Mitomycin C)
Study: 6693604
Drug: 0.3% anthralin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% anthralin ointment for 10 minutes daily
Study: 6693604
Drug: Conventional strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strength (0.1%-0.5%) anthralin ointment overnight
Study: 6693604
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration anthralin (0.5%-3%) for short contact periods of 10 minutes daily
Study: 6693604
Drug: Topical steroid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid, difluorosone diacetate
Study: 27005817
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele carriers of rs13431554
Study: 19882176
Drug: Single 150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 150-mg oral dose of casopitant
Study: 19882176
Drug: 3-day IV/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day IV/oral casopitant
Study: 19882176
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral casopitant vs Control
Study: 19882176
Drug: 3-day IV/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day IV/oral casopitant vs Control
Study: 16889952
Drug: Flixotide Diskus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flixotide Diskus (FP) 500-0 mcg/day
Study: 16889952
Drug: Pulmicort Turbuhaler
Normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Turbuhaler (BUD) 800-0 mcg/day
Study: 16529064
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (rivastigmine)
Study: 31811128
Drug: No primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No primaquine treatment
Study: 8557961
Drug: Amiloride+hydrochlorothiazide (2.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride+hydrochlorothiazide (2.5/25 mg once a day)
Study: 6863363
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional guanethidine
Study: 6863363
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional reserpine
Study: 28376877
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine
Study: 30548977
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol + lorazepam
Study: 30457119
Drug: Fast motion-including
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast motion-including dose reconstruction for proton pencil beam scanning
Study: 26924621
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh reinforcement during stoma closure
Study: 21565149
Drug: Indoor Residual
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor Residual Spray (IRS)
Study: 17052140
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication monitoring
Study: 12737331
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (low-level laser therapy)
Study: 11059532
Drug: i.v. polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. polyethylene glycol‐treated human immunoglobulin at 200 mg/kg per day
Study: 11059532
Drug: i.v. polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. polyethylene glycol‐treated human immunoglobulin at 400 mg/kg per day
Study: 11059532
Drug: freeze‐dried sulfonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: freeze‐dried sulfonated human immunoglobulin at 200 mg/kg per day
Study: 9080749
Drug: Resilient mandibular
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resilient mandibular bar-retained overdenture on two implants
Study: 9080749
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in the maxilla splinted by a rigidly cast bar
Study: 9080749
Drug: Overdenture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture therapy
Study: 7118065
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg p.o.)
Study: 2439821
Drug: Bopindolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (1 mg p.o.)
Study: 24394187
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B virus (HBV) envelope DNA vaccine
Study: 21628602
Drug: NAP/ESO tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAP/ESO tablet (500 mg EC naproxen + 20 mg non-EC esomeprazole magnesium)
Study: 21628602
Drug: EC naproxen
Normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC naproxen tablet alone
Study: 21628602
Drug: EC esomeprazole
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EC esomeprazole magnesium capsule alone
Study: 21628602
Drug: EC naproxen
Normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC naproxen tablet + EC esomeprazole magnesium capsule
Study: 20032480
Drug: Maternal nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nutritional status and supplement intake
Study: 18721511
Drug: Moderate statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate statin therapy
Study: 18222355
Drug: Intensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive and moderate statin therapy
Study: 15009510
Drug: Single melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single melatonin pill (5 mg)
Study: 15009510
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of light pulse and melatonin
Study: 11587165
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day of oral amlodipine
Study: 11587165
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amlodipine (baseline) + 5 mg of amlodipine (additional)
Study: 11587165
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amlodipine (baseline) + 25 mg of hydrochlorothiazide (HCTZ)
Study: 11587165
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amlodipine (baseline) + 20 mg of benazepril
Study: 7988255
Drug: Functional Living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Living Index‐Cancer (FLIC) administered to patients
Study: 7988255
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of chemotherapy
Study: 3108159
Drug: Carbohydrate in
Normalized name: Soy-based no added carbohydrate infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate in combination with fat emulsions (fat group)
Study: 3108159
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate solutions (carbohydrate group)
Study: 26047766
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (0.315 g per capsule, 3 capsules daily)
Study: 22262230
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg every 12 hours for 4 days
Study: 22262230
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg every 24 hours for 4 days
Study: 20522656
Drug: Comprehensive specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive specific care plan with standardised twice yearly consultation
Study: 16929239
Drug: Arginine-enhanced formula
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-enhanced formula (17 g/day)
Study: 16138795
Drug: Home care
Normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home care treatment delivered by primary care teams
Study: 16138795
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment as usual
Study: 11856154
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy plus six cycles of chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by tamoxifen 20 mg daily for 5 years
Study: 11856154
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (historical control population who never received systemic therapy)
Study: 11856154
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with positive and negative hormone receptor status
Study: 7869147
Drug: Oral instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral instructions by certified nurse-midwife in addition to written instructions (Group 2, n = 45)
Study: 2673079
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily dose of hydroxychloroquine sulphate
Study: 2673079
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily dose of hydroxychloroquine sulphate
Study: 347232
Drug: Full-cream milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-cream milk powder (control)
Study: 25966679
Drug: Periarticular infiltrations
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltrations and continuous post-operative intra-articular infusion of local anaesthetics (PIAC group)
Study: 25037695
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with potential up-titration to 150 mg Q2W at week 12 if LDL-C was ≥ 70 mg/dL at week 8.
Study: 25037695
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day.
Study: 25037695
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W before up-titration at week 12.
Study: 25037695
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions for Alirocumab.
Study: 25037695
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions for Ezetimibe.
Study: 19574013
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of MMF (mycophenolate mofetil)
Study: 19574013
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg bid of MMF (mycophenolate mofetil)
Study: 15022114
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with Gemcitabine
Study: 11885184
Drug: Hydroxyapatite-coated grooved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite-coated grooved implants
Study: 12500876
Drug: Hydroxyapatite grooved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite grooved and screw implants
Study: 12500876
Drug: Hydroxyapatite-coated cylinder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite-coated cylinder and grooved implants
Study: 12500876
Drug: Non-hydroxyapatite-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hydroxyapatite-coated implants
Study: 7970010
Drug: Tizanidine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (maximum dosage of 36 mg/d)
Study: 30009640
Drug: Diclofenac 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.1% (four times daily for 28 days)
Study: 30009640
Drug: Bromfenac 0.09%
Normalized name: Bromfenac 0.09% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 0.09% (twice daily for 14 days)
Study: 30009640
Drug: Steroid-antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-antibiotic combination (Control Group 3)
Study: 28440351
Drug: HyperSPACE (Hyper
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperSPACE (Hyper SPectral Analysis for Characterization in Echography) method applied before and after laser treatment